{
  "meta": {
    "title": "Transplant_Surgery",
    "url": "https://brainandscalpel.vercel.app/transplant-surgery-2f4d1831.html",
    "scrapedAt": "2025-11-29T18:41:12.689Z"
  },
  "questions": [
    {
      "id": 17288,
      "choices": [
        {
          "id": 69112,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Brain dead donor who is an identical twin</span></span></span></p>"
        },
        {
          "id": 69113,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Living donor who is an identical twin</span></span></span></p>"
        },
        {
          "id": 69114,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Brain dead donor who has the same blood group</span></span></span></p>"
        },
        {
          "id": 69115,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Living donor who has the same blood group</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of these is the ideal donor for organ transplant?</span></span></span></p>",
      "unique_key": "Q3400947",
      "question_audio": null,
      "question_video": null,
      "map_id": 16976,
      "difficulty_level": "intermediate",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Living donor who is an identical twin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A <strong>living donor</strong> who is an <strong>identical twin</strong> is the <strong>ideal choice</strong> for <strong>organ donation</strong>. This is because there would be a <strong>perfect HLA match</strong>, which is critical for <strong>reducing</strong> the <strong>risk</strong> of <strong>allograft</strong> <strong>rejection</strong>, and the organ would not have been subjected to any ischemic changes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A brain-dead donor who is an identical twin would be an <strong>excellent match</strong> in terms of <strong>HLA compatibility</strong>. However, the organs may have <strong>suffered</strong> from the <strong>events leading</strong> to <strong>brain death</strong> and subsequent <strong>changes in physiology.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. A brain-dead donor who has the same blood group <strong>can be a suitable donor</strong>, but <strong>without</strong> the <strong>genetic matching</strong> of an <strong>identical twin</strong>, there is a <strong>higher risk of rejection</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. A living donor who has the <strong>same blood group</strong> is <strong>better</strong> than a <strong>deceased donor</strong> in terms of organ quality, but the <strong>risk of rejection</strong> would <strong>still be higher</strong> compared to an identical twin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The ideal organ donor is a living donor who is an <strong>identical twin</strong> of the recipient due to the <strong>perfect HLA match</strong> and the <strong>optimal condition</strong> of the <strong>donated organ</strong>, which significantly <strong>reduces</strong> the <strong>risk of rejection</strong> and <strong>improves transplant outcomes</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transplants from <strong>live donors</strong> have a <strong>number of advantages</strong> <strong>over deceased</strong> <strong>donor organs</strong>. Live donor organ from <strong>healthy individuals</strong> <strong>without</strong> the <strong>comorbidities</strong> commonly seen in <strong>deceased donors</strong>. </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the <strong>agonal period</strong>, <strong>before death</strong>, <strong>deceased donors</strong> exhibit <strong>marked changes</strong> in physiology related to a <strong>catecholamine storm</strong> and this can cause <strong>organ dysfunction</strong>. Clearly, live donor organs are not subjected to this insult.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Allograft rejection is directed against human leukocyte antigens (HLAs)</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. These are a group of cell surface glycoprotein molecules. HLA molecules are divided into <strong>class I (A, B and C) and class II (DR, DP and DQ).</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">They are <strong>highly polymorphic</strong>, i.e., their <strong>amino acid sequences</strong> differ widely <strong>between individuals</strong>. To give an example, there are <strong>&gt; 1000 variants</strong> of the <strong>HLA-B gene</strong>. This genetic variability means that <strong>most transplant donors</strong> and <strong>recipients</strong> have <strong>different HLA profiles</strong>. <strong>HLA profiles will be the same in identical twins, hence chance of mismatch is low.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love, 28<sup>th</sup> Ed. Pg 1597-99</span></span></strong></p>",
      "correct_choice_id": 69113,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17289,
      "choices": [
        {
          "id": 69116,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sirolimus</span></span></p>"
        },
        {
          "id": 69117,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tacrolimus </span></span></span></p>"
        },
        {
          "id": 69118,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Azathioprine </span></span></span></p>"
        },
        {
          "id": 69119,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mycophenolate Mofetil</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old male has recently undergone a successful kidney transplant. To prevent graft rejection, his medical team plans to initiate maintenance immunosuppression therapy. Which of the following drugs is a mammalian target of rapamycin (mTOR) inhibitor that is suitable for this purpose?</span></span></span></p>",
      "unique_key": "Q7270776",
      "question_audio": null,
      "question_video": null,
      "map_id": 16977,
      "difficulty_level": "intermediate",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Sirolimus</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sirolimus is an <strong>mTOR inhibitor</strong> that is used in <strong>maintenance immunosuppression therapy</strong> after <strong>kidney transplantation</strong> to <strong>prevent organ rejection</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Tacrolimus</strong> is a <strong>calcineurin inhibitor</strong>, not an mTOR inhibitor, and is used for <strong>immunosuppression</strong> in <strong>transplant patients</strong>, but it works via a different mechanism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Azathioprine</strong> is an <strong>antiproliferative agent</strong> and is used as an <strong>immunosuppressant</strong>; however, it does not inhibit mTOR.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Mycophenolate mofetil</strong> is also an <strong>antiproliferative agent</strong> that <strong>inhibits</strong> the <strong>proliferation of T and B cells</strong> but is not an mTOR inhibitor.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sirolimus is a <strong>mammalian target</strong> of <strong>rapamycin</strong> (<strong>mTOR</strong>) <strong>inhibitor</strong> used in the <strong>maintenance phase</strong> of <strong>immunosuppression</strong> following <strong>kidney transplantation</strong> to <strong>prevent graft rejection</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drugs used for immunosuppression in a patient for kidney transplant are:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol style=\"list-style-type:upper-alpha\">\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calcineurin inhibitors</span></strong></span></span></li>\r\n</ol>\r\n\r\n<ul style=\"list-style-type:circle\">\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclosporine</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tacrolimus</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol start=\"2\" style=\"list-style-type:upper-alpha\">\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antiproliferative agents </span></strong></span></span></li>\r\n</ol>\r\n\r\n<ul style=\"list-style-type:circle\">\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Azathioprine</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mycophenolic acid</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"margin-left:72px\">&nbsp;</p>\r\n\r\n<ol start=\"3\" style=\"list-style-type:upper-alpha\">\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mammalian target of rapamycin (mTOR) inhibitors </span></strong></span></span></li>\r\n</ol>\r\n\r\n<ul style=\"list-style-type:circle\">\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sirolimus</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rapamycin</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Everolimus</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"margin-left:96px\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Immunosuppression for transplantation has two phases:</strong> <strong>Induction</strong> and <strong>maintenance</strong>. Induction therapy commonly consists of a combination of <strong>high-dose intravenous steroids</strong> and the <strong>anti-CD25 monoclonal antibody basiliximab, which blocks IL-2 receptors</strong>. Other induction agents for high-risk cases are ATG and the monoclonal antibody alemtuzumab.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love&rsquo;s short practice of surgery 28<sup>th</sup> edition pg 1601-02</span></span></strong></p>",
      "correct_choice_id": 69116,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17292,
      "choices": [
        {
          "id": 69128,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The donor kidney is transplanted heterotopically into one of the iliac fossae</span></span></span></p>"
        },
        {
          "id": 69129,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The transplant renal vein is anastomosed end to side to the external or common iliac vein. </span></span></span></p>"
        },
        {
          "id": 69130,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The renal artery is anastomosed end to side to the external iliac artery in a deceased donor</span></span></span></p>"
        },
        {
          "id": 69131,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Donor ureter is anastomosed to recipient ureter via a spatulated anastomosis</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Identify the incorrect statement of the following about the technique of renal transplant?</span></span></span></p>",
      "unique_key": "Q9686213",
      "question_audio": null,
      "question_video": null,
      "map_id": 16980,
      "difficulty_level": "intermediate",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Donor ureter is anastomosed to recipient ureter via a spatulated anastomosis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>incorrect</strong>. In renal transplant surgery, the <strong>donor ureter</strong> is typically <strong>anastomosed directly</strong> to the <strong>recipient&#39;s bladder</strong>, not to the recipient&#39;s ureter, using the <strong>Lich&ndash;Gr&eacute;goir technique</strong> to create a <strong>new vesicoureteral junction</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is a <strong>correct statement</strong> as the <strong>donor kidney</strong> is typically placed in a location different from the <strong>original kidneys</strong>, which is in the <strong>retroperitoneal iliac fossa</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. This is the <strong>standard practice</strong> for the <strong>venous anastomosis</strong> in <strong>renal transplantation</strong>, making this statement <strong>correct</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. This is <strong>also correct</strong> as the <strong>renal artery</strong> can be <strong>anastomosed</strong> to the <strong>external iliac artery</strong> via a <strong>&ldquo;Carrel patch&rdquo;</strong> which can be <strong>obtained</strong> in <strong>deceased donor</strong>. In living donor transplants, the <strong>donor renal artery</strong> is <strong>anastomosed</strong> to <strong>recipient internal iliac artery</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In <strong>renal transplantation</strong>, the donor ureter is not anastomosed to the recipient ureter but is <strong>instead anastomosed</strong> to the <strong>bladder</strong> as an <strong>extra-vesical anastomosis</strong> using the <strong>Lich&ndash;Gr&eacute;goir technique</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal transplant operative technique </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The donor kidney is transplanted <strong>heterotopically into one of the iliac fossa</strong> via a curvilinear incision. </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The transplant <strong>renal vein is anastomosed end to side</strong> to the external or common iliac vein. </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>renal artery is anastomosed either end to side</strong> to the external or common iliac artery (via Carrels aortic patch) or end to end to the divided internal iliac artery</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The internal iliac artery is used more commonly for live donor kidneys because of the lack of an aortic patch. </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">After revascularisation of the transplant kidney the </span><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ureter is anastomosed to the bladder as an extra-vesical only</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> (the Lich&ndash;GreÃÅgoir technique) </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:&nbsp;</span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bailey and Love&rsquo;s short practice of surgery 28<sup>th</sup> edition pg 1604</span></span></strong></p>",
      "correct_choice_id": 69131,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17294,
      "choices": [
        {
          "id": 69136,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sub-Optimal Kidney Transplant</span></span></span></p>"
        },
        {
          "id": 69137,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dual Kidney Transplant</span></span></span></p>"
        },
        {
          "id": 69138,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Additional Kidney Transplant</span></span></span></p>"
        },
        {
          "id": 69139,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Domino Kidney Transplant</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transplantation of a pair of marginal quality kidneys from the same donor into one recipient in order to provide adequate nephron mass is called as?</span></span></p>",
      "unique_key": "Q6372998",
      "question_audio": null,
      "question_video": null,
      "map_id": 16982,
      "difficulty_level": "difficult",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Dual Kidney Transplant</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dual kidney transplant is the correct term for <strong>transplanting two kidneys</strong> from the <strong>same donor</strong> into a <strong>single recipient</strong>, which is done to <strong>provide sufficient nephron mass</strong>, especially when the <strong>kidneys</strong> are from an <strong>expanded criteria</strong> <strong>donor</strong> or are of <strong>marginal quality</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sub-optimal kidney transplant typically refers to a <strong>transplant</strong> involving a <strong>kidney</strong> that is not in optimal condition, but can be used a <strong>bridge</strong> to <strong>formal renal transplant</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. Additional kidney transplant is not a standard term used in transplant medicine for this scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. Domino kidney transplant refers to a <strong>specific type of transplant</strong> where an <strong>organ or tissue</strong> is <strong>transplanted</strong> from <strong>one person</strong> to <strong>another</strong> and then from that <strong>person</strong> to <strong>another recipient</strong>, which is not the case described.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dual kidney transplantation is the process where <strong>two marginal quality kidneys</strong> from the <strong>same donor</strong> are <strong>transplanted</strong> into <strong>one recipient</strong> to ensure <strong>adequate nephron mass</strong> and <strong>function</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dual kidney transplantation </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This involves the transplantation of a pair of marginal quality kidneys from the same donor into one recipient in order to provide adequate nephron mass. </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Both kidneys can be placed in the same iliac fossa</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This approach is used for kidneys from elderly Donor after Circulatory Death and so-called <strong>expanded criteria donors, which are defined by age &gt; 60 years or age &gt;50 years with at least two of the following:</strong> hypertension; terminal creatinine &gt;133 &mu;mol/L; death from stroke. </span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"margin-left:168px\">&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:&nbsp;</span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bailey and Love&rsquo;s short practice of surgery 28<sup>th</sup> edition pg 1604</span></span></strong></p>",
      "correct_choice_id": 69137,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17296,
      "choices": [
        {
          "id": 69144,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recurrence of Disease</span></span></span></p>"
        },
        {
          "id": 69145,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal Vein Thrombosis</span></span></span></p>"
        },
        {
          "id": 69146,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal Artery Stenosis</span></span></span></p>"
        },
        {
          "id": 69147,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dehydration </span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of these is not a cause of early graft dysfunction in renal transplant patient?</span></span></span></p>",
      "unique_key": "Q3294074",
      "question_audio": null,
      "question_video": null,
      "map_id": 16984,
      "difficulty_level": "intermediate",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Recurrence of Disease</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recurrence of disease is not typically a cause of early graft dysfunction, as the recurrence of the <strong>original kidney disease</strong> in the <strong>transplanted organ</strong> <strong>generally takes time</strong> to <strong>develop</strong> and is not expected to present immediately post-transplant.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Renal vein thrombosis is a <strong>significant cause</strong> of <strong>early graft dysfunction</strong> due to the <strong>immediate impairment</strong> of <strong>blood flow</strong> it can cause in the <strong>transplanted kidney</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Renal artery stenosis can lead to <strong>early graft dysfunction</strong> by <strong>reducing blood flow</strong> to the <strong>transplanted kidney</strong>, causing <strong>ischemia</strong> and <strong>potentially acute renal failure</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Dehydration can cause <strong>pre-renal acute kidney injury</strong> by <strong>decreasing blood flow</strong> to the <strong>kidneys</strong>, leading to <strong>early graft dysfunction</strong> if <strong>severe</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recurrence of the original disease is not a common cause of early graft dysfunction in renal transplant patients; as such recurrences typically occur <strong>later</strong> in the <strong>post-transplant course</strong>. <strong>Early graft dysfunction</strong> is more often caused by factors such as <strong>acute rejection, vascular complications, infections, or technical issues</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Causes of early graft dysfunction </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Any rise&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">in <strong>serum creatinine</strong> of <strong>&gt;10% of baseline</strong> or <strong>&ge;20 &mu;mol/L</strong> should be considered as <strong>acute allograft dysfunction</strong> that <strong>requires investigation</strong>. Possible causes are: </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute Rejection (Antibody Mediated or Cell Mediated) </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calcineurin Inhibitor Toxicity </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dehydration </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Urinary Tract Infection or Pyelonephritis </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Any other source of Sepsis </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal Vein or Renal Artery Thrombosis </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ureteric Obstruction or Urine Leak </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:&nbsp;</span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bailey and Love&rsquo;s short practice of surgery 28<sup>th</sup> edition pg 1606</span></span></strong></p>",
      "correct_choice_id": 69144,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17298,
      "choices": [
        {
          "id": 69152,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute Rejection </span></span></span></p>"
        },
        {
          "id": 69153,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic Rejection </span></span></span></p>"
        },
        {
          "id": 69154,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal Artery Stenosis </span></span></span></p>"
        },
        {
          "id": 69155,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dehydration</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#374151\">A 58-year-old male who underwent a kidney transplant 7 years ago presents with gradually worsening renal function over the past year. He has no signs of infection, maintains good hydration, and reports compliance with his immunosuppressive medications. A renal biopsy reveals interstitial fibrosis and tubular atrophy without evidence of acute inflammatory changes. Which of the following is the most likely cause of this patient&#39;s renal dysfunction?</span></span></span></p>",
      "unique_key": "Q3032621",
      "question_audio": null,
      "question_video": null,
      "map_id": 16986,
      "difficulty_level": "beginner",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Chronic Rejection</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic rejection, which can manifest as <strong>either chronic AMR</strong> or <strong>chronic CMR</strong>, is a significant cause of <strong>long-term graft dysfunction</strong> and is considered the <strong>most common cause</strong> of <strong>late graft failure</strong>. The biopsy findings are <strong>typical</strong> of <strong>chronic rejection</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute rejection, <strong>both antibody-mediated (AMR)</strong> and <strong>cell-mediated (CMR)</strong>, can lead to <strong>early graft dysfunction</strong> (within few months).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. Renal artery stenosis can lead to graft dysfunction due to <strong>ischemia</strong>; however, it is less common than chronic rejection and doesn&rsquo;t match the biopsy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. Dehydration can cause <strong>acute pre-renal failure</strong> but is not a common cause of long-term graft failure in kidney transplant patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic rejection is the <strong>most common cause</strong> of <strong>graft failure/dysfunction</strong> in <strong>kidney transplant</strong>, typically presenting as <strong>progressive organ dysfunction</strong> over time due to <strong>immunological factors</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Causes of long-term graft dysfunction </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immunological </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul style=\"list-style-type:circle\">\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic AMR (anti-body mediated rejection)</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute CMR (cell mediated rejection) or AMR, which can occur at any time</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-immunological</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul style=\"list-style-type:circle\">\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pre-existing damage in the donor kidney (especially relevant to DCD and extended criteria donor kidneys) </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Early ischaemia - Reperfusion injury </span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic calcineurin nephrotoxicity </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ureteric or bladder outflow obstruction </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recurrent urinary tract infection or pyelonephritis </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BK polyomavirus nephropathy </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recurrent native disease: glomerulonephritis; focal segmental glomerulosclerosis; immunoglobulin A nephropathy </span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal artery stenosis </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Poorly controlled hypertension </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dyslipidaemia </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:&nbsp;</span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bailey and Love&rsquo;s short practice of surgery 28<sup>th</sup> edition pg 1606-1607</span></span></strong></p>",
      "correct_choice_id": 69153,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17300,
      "choices": [
        {
          "id": 69160,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Post-Transplant Lymphoproliferative Disorder (PTLD) </span></span></span></p>"
        },
        {
          "id": 69161,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Squamous Cell Carcinoma of the Skin </span></span></span></p>"
        },
        {
          "id": 69162,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Leukemia</span></span></span></p>"
        },
        {
          "id": 69163,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Kaposi&rsquo;s Sarcoma</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 63-year-old male, who received a kidney transplant 2 years ago and has been on chronic immunosuppressive therapy, presents with multiple hyperkeratotic lesions on sun-exposed areas of the skin. Biopsy of one lesion confirms malignancy. Which of the following is the most likely diagnosis?</span></span></span></p>",
      "unique_key": "Q3762615",
      "question_audio": null,
      "question_video": null,
      "map_id": 16988,
      "difficulty_level": "intermediate",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Squamous Cell Carcinoma of the Skin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Squamous cell carcinoma of the skin is the most <strong>common malignancy</strong> seen in <strong>post-transplant patients</strong> due to <strong>chronic immunosuppression</strong>, particularly in <strong>sun-exposed areas</strong>, matching the presentation described.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. PTLD refers to a <strong>range</strong> of <strong>lymphoid proliferations</strong> that can occur following <strong>transplantation</strong> due to <strong>immunosuppression</strong>. However, it does not present with hyperkeratotic skin lesions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. Leukemia can occur in the <strong>post-transplant setting</strong> but would not present with localized skin lesions, but with pancytopenia and splenomegaly.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. Kaposi&rsquo;s sarcoma can occur in <strong>transplant patients</strong> but <strong>typically presents</strong> as <strong>violaceous plaques</strong> or <strong>nodules</strong> and is less common than squamous cell carcinoma in these patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>most common malignancy</strong> seen <strong>post-transplant</strong> in patients on <strong>immunosuppressive therapy</strong> is <strong>squamous cell carcinoma</strong> of the <strong>skin</strong>, often occurring on <strong>sun-exposed areas</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common malignancy seen post-transplant immunosuppressive therapy is <strong>Squamous cell carcinoma</strong> of skin</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Complications of immunosuppression:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Infections: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"margin-left:28px\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">1. CMV</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> - 4 to 8 weeks Post-Transplant - Pneumonia/Retinitis/Encephalitis</span></span></span></p>\r\n\r\n<p style=\"margin-left:28px\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment - Valganciclovir</span></span></span></p>\r\n\r\n<p style=\"margin-left:28px\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">2. Pneumocystis jirovecii</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> - Fungal Pneumonia</span></span></span></p>\r\n\r\n<p style=\"margin-left:28px\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Malignancy: -</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Skin Cancers (MC- Squamous Cell Carcinoma)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Bailey and Love 27<sup>th</sup> Ed. Pg 1541, Box 82.5</span></span></strong></p>",
      "correct_choice_id": 69161,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17304,
      "choices": [
        {
          "id": 69176,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Living Related Donor</span></span></span></p>"
        },
        {
          "id": 69177,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Living Unrelated Donor</span></span></span></p>"
        },
        {
          "id": 69178,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Deceased Brain-Dead Donor</span></span></span></p>"
        },
        {
          "id": 69179,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Deceased Circulatory Dead Donor</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Maastricht grading is used to categorize?</span></span></span></p>",
      "unique_key": "Q9998075",
      "question_audio": null,
      "question_video": null,
      "map_id": 16992,
      "difficulty_level": "intermediate",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Deceased Circulatory Dead Donor</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The modified <strong>Maastricht classification</strong> is widely used to <strong>categorise DCD</strong> (<strong>Donation after Circulatory Death</strong>).</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/30/picture1_Cev8cvf.jpg\" style=\"height:294px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Controlled grades of donors (<strong>III/IV</strong>) are <strong>more suitable</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bailey and Love&rsquo;s short practice of surgery 28<sup>th</sup> edition pg 1596</span></strong></span></span></p>",
      "correct_choice_id": 69179,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17305,
      "choices": [
        {
          "id": 69180,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Severe Acute Pancreatitis with Sepsis </span></span></span></p>"
        },
        {
          "id": 69181,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Malignant Melanoma</span></span></span></p>"
        },
        {
          "id": 69182,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prion Disease </span></span></span></p>"
        },
        {
          "id": 69183,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary CNS Tumor</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 46-year-old male with a history of a brain lesion treated with surgical resection and no evidence of metastasis is evaluated for kidney transplantation. Which of the following conditions in the patient&#39;s history is not considered an absolute contraindication to transplant?</span></span></span></p>",
      "unique_key": "Q9338565",
      "question_audio": null,
      "question_video": null,
      "map_id": 16993,
      "difficulty_level": "intermediate",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Primary CNS Tumor</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A primary CNS tumor, especially if it is a <strong>non-metastatic lesion</strong> that has been <strong>treated</strong>, is not an absolute contraindication to organ transplantation. This is an <strong>exception</strong> to the <strong>rule against transplanting</strong> in the <strong>setting of malignancy</strong> due to the <strong>low risk</strong> of <strong>metastasis</strong> <strong>outside the CNS</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Severe acute pancreatitis with sepsis is typically a <strong>contraindication</strong>, until the <strong>sepsis</strong> is <strong>under control</strong>. <strong>Active systemic sepsis</strong> at the <strong>time of transplant</strong> would be an <strong>absolute contraindication</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. Melanoma is an <strong>absolute contraindication</strong> to <strong>transplant</strong>. Non-melanotic skin tumors are not.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Prion disease</strong>, such as <strong>Creutzfeldt-Jakob disease</strong>, is an <strong>absolute contraindication</strong> to <strong>organ transplantation</strong> due to the <strong>high risk</strong> of <strong>transmitting</strong> the <strong>disease</strong> through <strong>transplanted tissues</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary CNS tumors, particularly those that are <strong>localized</strong> and have been treated without evidence of metastasis, are not considered an absolute contraindication to organ transplantation. This is in contrast to systemic malignancies and certain untreatable or high-risk infections.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Contraindication to organ transplant:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Absolute </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Creutzfeldt Jacobson Disease (Prion Disease)</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Active Systemic Sepsis</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Malignancy in previous 5 years (except Primary CNS tumour, Non-Melanotic Skin Ca and CIS of uterus)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Relative</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">As a further response to the <strong>organ donor shortage</strong>, organs are now being <strong>transplanted from donors</strong> with <strong>meningitis/encephalitis</strong>, <strong>human immunodeficiency virus (HIV)</strong>, <strong>hepatitis B</strong> and <strong>C</strong> and <strong>high-risk behaviour</strong> with the <strong>potential</strong> for <strong>blood-borne infection</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love&rsquo;s short practice of surgery 28<sup>th</sup> edition pg 1596-97</span></span></strong></p>",
      "correct_choice_id": 69183,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17310,
      "choices": [
        {
          "id": 69200,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metabolic Alkalosis</span></span></span></p>"
        },
        {
          "id": 69201,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chemical Cystitis</span></span></span></p>"
        },
        {
          "id": 69202,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reflux Pancreatitis</span></span></span></p>"
        },
        {
          "id": 69203,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prostatic Abscess</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old type 1 diabetic with ESRD underwent simultaneous pancreatic-kidney transplant (SPK). Which of these is not a complication of bladder drainage of transplanted pancreas?</span></span></span></p>",
      "unique_key": "Q2249738",
      "question_audio": null,
      "question_video": null,
      "map_id": 16998,
      "difficulty_level": "intermediate",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Metabolic Alkalosis</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If <strong>transplanted pancreas</strong> is <strong>drained</strong> into <strong>bladder</strong> instead of <strong>small bowel</strong>, there is <strong>loss of bicarbonates</strong> from the <strong>pancreatic secretions</strong>, leading to <strong>metabolic acidosis</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/30/picture2.jpg\" style=\"height:502px; width:1000px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love&rsquo;s short practice of surgery 28<sup>th</sup> edition pg 1627</span></strong></span></span></p>",
      "correct_choice_id": 69200,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17311,
      "choices": [
        {
          "id": 69204,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hepatic Artery </span></span></span></p>"
        },
        {
          "id": 69205,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Portal Vein </span></span></span></p>"
        },
        {
          "id": 69206,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bile Duct </span></span></span></p>"
        },
        {
          "id": 69207,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IVC</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old patient with Child C Cirrhosis and Hepatitis C is undergoing a liver transplant. Which anatomical structure should the surgeon prepare to anastomose first in the recipient?</span></span></span></p>",
      "unique_key": "Q2003889",
      "question_audio": null,
      "question_video": null,
      "map_id": 16999,
      "difficulty_level": "intermediate",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. IVC</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: The IVC, <strong>both supra-hepatic</strong> and <strong>infra-hepatic</strong>, is usually the <strong>first part</strong> to be <strong>anastomosed</strong> during <strong>liver transplantation</strong> to <strong>establish venous outflow</strong> from the <strong>liver</strong>, which is <strong>critical</strong> to <strong>providing immediate blood drainage</strong> from the <strong>graft</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>first structure</strong> to be <strong>anastomosed</strong> in the <strong>recipient</strong> of a <strong>liver transplant</strong> is the <strong>IVC</strong>, specifically <strong>starting</strong> with the <strong>supra-hepatic IVC</strong>, followed by the <strong>infra-hepatic IVC</strong>, to <strong>establish adequate venous outflow</strong> from the <strong>liver</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Order of <strong>anastomosis</strong> in <strong>recipient</strong> of <strong>liver transplant</strong> is: </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Supra-hepatic IVC</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Infra-hepatic IVC </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Portal Vein</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hepatic Artery </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bile duct</span></span></span></li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love&rsquo;s short practice of surgery 28<sup>th</sup> edition pg 1610-1611</span></span></strong></p>",
      "correct_choice_id": 69207,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17312,
      "choices": [
        {
          "id": 69208,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Skin</span></span></p>"
        },
        {
          "id": 69209,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gastrointestinal tract</span></span></p>"
        },
        {
          "id": 69210,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liver</span></span></p>"
        },
        {
          "id": 69211,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lung</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient with graft-versus-host disease (GVHD) following a hematopoietic stem cell transplant, which organ is least likely to affect by this condition?</span></span></span></p>",
      "unique_key": "Q6370836",
      "question_audio": null,
      "question_video": null,
      "map_id": 17000,
      "difficulty_level": "intermediate",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Lung</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The lung is considered the <strong>least affected organ</strong> in <strong>GVHD</strong> compared to the <strong>skin, liver,</strong> and <strong>gastrointestinal tract</strong>, although it can be involved in <strong>chronic</strong> and <strong>late-stage presentations</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. The skin is <strong>commonly affected</strong> in GVHD, presenting with <strong>rashes</strong> and can progress to <strong>desquamation</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The gastrointestinal tract is <strong>frequently involved</strong> in GVHD, which can <strong>manifest</strong> as <strong>diarrhea, abdominal pain</strong>, and <strong>gastrointestinal bleeding</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The liver can be <strong>affected</strong> in GVHD, leading to <strong>elevated liver enzymes</strong>, <strong>jaundice</strong>, and <strong>cholestasis</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While any organ can be <strong>affected</strong> by <strong>graft-versus-host disease</strong>, the lung is typically the <strong>least affected organ</strong> compared to the <strong>skin, liver</strong>, and <strong>gastrointestinal tract</strong>, which are more <strong>commonly</strong> involved in <strong>acute presentations</strong> of the <strong>disease</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Graft-versus-host disease (GVHD) occurs due to&nbsp;<strong>the presence of immunocompetent T lymphocytes in the graft attacking the immunodeficient recipient tissue due to histocompatibility differences within 100 days</strong>, causing tissue damage.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Organ most affected by GVHD - <strong>Skin</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Organ least affected by GVHD - <strong>Lung</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Any organ can be affected in GVH reaction. The most important is the involvement of immune system, skin, liver and intestines.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Online reference &ndash; </span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bailey and Love 27<sup>th</sup> Ed. Pg 1537</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.</span></span></p>",
      "correct_choice_id": 69211,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17315,
      "choices": [
        {
          "id": 69220,
          "text": "<p><span style=\"font-size:18px;\">Most common indication in a child is biliary atresia</span></p>"
        },
        {
          "id": 69221,
          "text": "<p><span style=\"font-size:18px;\">Liver transplant may be done in liver malignancies</span></p>"
        },
        {
          "id": 69222,
          "text": "<p><span style=\"font-size:18px;\">In auxiliary liver transplant, native liver is left in situ</span></p>"
        },
        {
          "id": 69223,
          "text": "<p><span style=\"font-size:18px;\">Liver is resistant to acute rejection</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:18px;\">Which of these is incorrect about liver transplant?</span></p>",
      "unique_key": "Q1167986",
      "question_audio": null,
      "question_video": null,
      "map_id": 17003,
      "difficulty_level": "intermediate",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:18px;\"><strong>Ans. D)&nbsp;Liver is resistant to acute rejection</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Option D:&nbsp;</strong>This statement is <strong>incorrect</strong>. The liver, like any transplanted organ, is <strong>susceptible</strong> to <strong>acute rejection</strong>. Although the liver may have a <strong>higher tolerance</strong> for <strong>immunologic insult</strong> compared to other <strong>solid organs</strong>, <strong>acute rejection</strong> can occur in <strong>all organs</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Option A.</strong>&nbsp;<strong>Biliary atresia</strong> is indeed the <strong>most common indication</strong> for <strong>liver transplantation</strong> in <strong>children</strong>, making this statement correct.</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Option B</strong>. Liver transplantation is an <strong>established</strong> treatment for <strong>selected patients</strong> with <strong>Hepato-Cellular Carcinoma</strong> (HCC) and <strong>fulfills</strong> specific criteria such as the <strong>Milan</strong> or <strong>UCSF criteria</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Option C.&nbsp;</strong>In auxiliary liver transplantation, part of the native liver is left in place, and a portion of a <strong>donor liver</strong> is <strong>implanted</strong>. This procedure may be considered for certain indications, making this statement correct.</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong><u>Educational objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\">The liver is <strong>not resistant </strong>to <strong>acute rejection</strong>; it is <strong>susceptible</strong> to <strong>acute rejection</strong> like any other transplanted organ, and <strong>acute cellular rejection</strong> is a <strong>common cause</strong> of <strong>graft dysfunction</strong> early <strong>after liver transplantation</strong>.</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:18px;\">In adults the <strong>most common causes are alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), chronic viral hepatitis (hepatitis B virus [HBV] and hepatitis C virus [HCV])</strong>. In the last two decades hepatitis-related CLD (HBV and HCV) was the most common indication for LT.</span></li><li><span style=\"font-size:18px;\">In children, who account for around 10‚Äì15% of all LTs, <strong>biliary atresia is the most common indication for transplantation.</strong></span></li><li><span style=\"font-size:18px;\">LTx is indicated as a <strong>curative treatment</strong> for <strong>selected patients</strong> with <strong>HCC</strong>, <strong>haemangioendothelioma</strong> and <strong>hepatoblastoma.</strong></span></li><li><span style=\"font-size:18px;\"><strong>Milan criteria</strong> (one lesion ‚â§5&nbsp;cm, or three or fewer lesions ‚â§3&nbsp;cm each)</span></li><li><span style=\"font-size:18px;\"><strong>UCSF criteria</strong> (one lesion ‚â§6.5&nbsp;cm, or three or fewer lesions ‚â§4.5&nbsp;cm each, with a total tumour diameter ‚â§8&nbsp;cm)</span></li><li><span style=\"font-size:18px;\"><strong>Auxiliary LT involves implanting a healthy liver graft placed either heterotopically or orthotopically while leaving all or part of the native liver intact.</strong> Auxiliary heterotopic LT, where the graft is implanted below the native liver, was proposed as an alternative to orthotopic LT.</span></li><li><span style=\"font-size:18px;\">Liver graft dysfunction can happen any time after transplantation; if not identified early and treated promptly, it can lead to graft loss. <strong>The most common presentation is an asymptomatic elevation of liver enzyme levels</strong>. Early after LT, <strong>acute cellular rejection is the most common cause</strong> of graft dysfunction and is usually treated by increasing the dose of immunosuppression.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong><u>Ref</u>: Bailey 28<sup>th</sup> Ed. Pg 1608, 1610, 1614, 1618.</strong></span></p>",
      "correct_choice_id": 69223,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31883,
      "choices": [
        {
          "id": 127402,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperacute Rejection occurs due to T Cell Mediated Destruction</span></span></span></p>"
        },
        {
          "id": 127403,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute Rejection occurs during first 6 Months</span></span></span></p>"
        },
        {
          "id": 127404,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic Rejection is the most common cause of Graft Failure</span></span></p>"
        },
        {
          "id": 127405,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic Rejection is characterized by Myo-Intimal Proliferation on Biopsy</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Identify the incorrect statement about graft rejection:</span></span></p>",
      "unique_key": "Q8458617",
      "question_audio": null,
      "question_video": null,
      "map_id": 22321,
      "difficulty_level": "intermediate",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Hyperacute Rejection occurs due to T Cell Mediated Destruction</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>incorrect</strong>. Hyperacute rejection is not primarily mediated by T cells. It is an <strong>immediate</strong> and <strong>severe form</strong> of <strong>rejection</strong> that occurs due to <strong>pre-existing antibodies</strong> <strong>against</strong> the <strong>graft</strong>, typically <strong>antibodies against ABO</strong> or <strong>human leukocyte antigens (HLA)</strong>. These antibodies lead to <strong>rapid complement activation</strong> and <strong>destruction</strong> of the <strong>transplanted organ</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is generally <strong>accurate</strong>. Acute rejection is most common in the <strong>early post-transplant period</strong>, and it often occurs within the <strong>first few months</strong> after <strong>transplantation</strong>. However, acute rejection can occur at <strong>any time post-transplant</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>correct</strong>. Chronic rejection can contribute to <strong>graft failure</strong> over time. <strong>Graft failure</strong> can result from various factors, including <strong>acute rejection</strong>, <strong>infections</strong>, <strong>vascular complications</strong>, and other non-immunological factors.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>generally accurate</strong>. <strong>Chronic rejection</strong> is associated with <strong>long-term changes</strong>, including <strong>fibrosis</strong> and <strong>myo-intimal proliferation</strong> in the <strong>blood vessels</strong> of the <strong>transplanted organ</strong>. This can be observed on <strong>biopsy</strong> as a characteristic feature of <strong>chronic rejection</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Types of Graft Rejection</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperacute rejection</span></strong></span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immediate graft destruction due to ABO or preformed anti-HLA antibodies </span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Characterised by intravascular thrombosis and interstitial haemorrhage</span></span></span><br />\r\n\t\t&nbsp;</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute rejection</span></strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Usually occurs during first 6 months</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">T-cell dependent</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">May be cell mediated, antibody mediated or both</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Usually reversible</span></span></span><br />\r\n\t\t&nbsp;</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic rejection</span></strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Occurs after first 6 months</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common cause of graft failure</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antibodies play an important role</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Noe-immune factors contribute to pathogenesis</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Characterised by myointimal proliferation in graft arteries leading to ischaemia and fibrosis</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey 27<sup>th</sup> Ed. PG 1535.</span></span></strong></p>",
      "correct_choice_id": 127402,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}